The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, ...

The WHO recommends vaccination against 12 deadly diseases in childhood, but how long does protection last, and how do they ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor (XNCR) and Alnylam (ALNY). Read more here.

These Phase 1b data, in 34 chronically infected hepatitis B patients, on nucleos(t ... declines in HBV surface antigen (HBsAg) ranging from -2.3 to -0.4 log10 IU/mL were observed in 7 patients ...

Hepatitis B is a liver infection that inflames the organ ... "They do so by exposing the body to an active ingredient called an antigen which triggers an immune response," Brull says.

Scientists from the College of Medicine of National Taiwan University and National Taiwan University Children's Hospital identified that the Hepatitis B e antigen (HBeAg) seroconversion in ...

However, researchers are working toward improving rates of “functional cure” which is achieved when levels of hepatitis B surface antigen (HBsAg) and HBV DNA become low enough to be ...

However, the prevalence of both virus infections was significantly higher among people tested in Cork where Hepatitis B surface antigen were present in over 1.1 per cent of cases – more than ...

Preclinical studies in mouse models have demonstrated that GIGA-2339 can neutralise and eliminate HBV's viral antigens and deoxyribonucleic ... of GIGA-2339 for hepatitis B treatment" was ...

The three-antigen vaccine is VBI’s sole FDA-approved ... on developing a “functional cure regimen” for chronic hepatitis B by zeroing in on its immunotherapeutic candidate VBI-2601.